List of Equetro drug patents

Equetro is owned by Validus Pharms.

Equetro contains Carbamazepine.

Equetro has a total of 1 drug patent out of which 0 drug patents have expired.

Equetro was authorised for market use on 10 December, 2004.

Equetro is available in capsule, extended release;oral dosage forms.

Equetro can be used as the recommended initial dose of equetro is 400mg/day given in divided doses, twice daily. the dose should be adjusted in 200mg daily increments to achieve optimal clinical response..

The generics of Equetro are possible to be released after 19 May, 2024.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6977253 VALIDUS PHARMS Methods for the treatment of bipolar disorder using carbamazepine
May, 2024

(1 year, 3 months from now)

Drugs and Companies using CARBAMAZEPINE ingredient

Market Authorisation Date: 10 December, 2004

Treatment: The recommended initial dose of equetro is 400mg/day given in divided doses, twice daily. the dose should be adjusted in 200mg daily increments to achieve optimal clinical response.

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of EQUETRO before it's patent expiration?
More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic